Expression of PTEN, p53 and p-glycoprotein in non-small cell lung cancer and their predictive values

Chinese Journal of Lung Cancer

Volumn 12, Issue 11, 2009, Pages 1213-1216

  Zhang, Honglan ^a   Shu, Hong ^a   Jiang, Weiguo ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Immunohistochemistry; Lung neoplasms; P glycoprotein; p53 gene; Prognosis; PTEN protein

Indexed keywords

GLYCOPROTEIN P; PARAFFIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESISTANCE; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PREDICTION AND FORECASTING; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE;

EID: 75349093621     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.11.17     Document Type: Article

References (14)

1. Noble J. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: A systematic review and practice guideline. J Thorac Oncol, 2006, 1(19): 1042-1058.
2. Donnenberg VS, Donnenberg AD. Multidrug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol, 2005, 45(8): 872-877.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
4. Steck PA, Pershouse MA, Tasser SA, et al. Identification of a can-didate tumor suppressor gene MMAC at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet, 1997, 15(4): 357-362.
5. Montenarh M. Biochemical properties of the growth suppressor, oncoprotein p53. Oncogene, 1992, 7(9): 1673-16780.
6. Mayo LD, Dixon JE, Durden DL, et al. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem, 2002, 277(7): 5484-5489.
7. Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistance cancer. Curr Drug Targets, 2000, 1(1): 85-99.
8. Tada Y, Wada M, Migita T, et al. Increased expression of mul-tidrug resistance2associated proteins in bladder cancer during clinical course and drug resistance to doxorubicin. Int J Cancer, 2002, 98(4): 630-635 .
9. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther, 2003, 10(19): 1636-1642.
10. Yan X, Fraser M, Qiu Q, et al. Over expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53 depentent manner. Gynecol Oncol, 2006, 102(2): 348-355.
11. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor oncoprotein network. Trends Biochem Sci, 2002, 27(9): 462-467.
12. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell, 1992, 70(4): 523-526.
13. Gregory F, Sullivan, Yang JM, et al. Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest, 2000, 105(9): 1261-1267.
14. Oliver B, Wolfgang W, Michael W. Modulation of MDR/MRP by wild type and mutant p53. J Clin Invest, 2001, 107(5): 643-645.